Monte Rosa Therapeutics Inc.
GLUE | NASDAQ
$12.26
+$0.13 (+1.07%)
At close: Sep 21, 2026, 4:00 PM ET
$12.71
+$0.45 (+3.67%)
Pre-market:
Sep 22, 2026, 4:24 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 123.67M | 75.62M | n/a | n/a | n/a | n/a |
Cost of Revenue | 8.36M | 8.12M | 6.22M | n/a | n/a | 537K |
Gross Profit | 115.32M | 67.5M | -6.22M | n/a | n/a | -537K |
Operating Income | -54.21M | -81.11M | -143.31M | -112.38M | -72.88M | -28.01M |
Interest Income | 12.94M | 10.57M | 9.33M | 3.76M | 46K | 9K |
Pretax Income | -39.72M | -70.13M | -135.01M | -108.5M | -73.96M | -35.88M |
Net Income | -38.63M | -72.7M | -135.35M | -108.5M | -73.96M | -35.88M |
Selling & General & Admin | 36.38M | 35.17M | 32.04M | 27.32M | 15.73M | 4.01M |
Research & Development | 141.5M | 121.56M | 105.05M | 85.06M | 57.16M | 23.47M |
Other Expenses | -8.36M | -8.12M | n/a | n/a | n/a | n/a |
Operating Expenses | 169.52M | 148.61M | 137.09M | 112.38M | 72.88M | 27.47M |
Interest Expense | n/a | n/a | n/a | 3.76M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 177.88M | 156.73M | 143.31M | 112.38M | 72.88M | 28.01M |
Income Tax Expense | -1.1M | 2.57M | 338K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 83.07M | 73.91M | 51.4M | 47.23M | 46.54M | 44M |
Shares Outstanding (Diluted) | 83.07M | 73.91M | 51.4M | 47.23M | 46.54M | 44M |
EPS (Basic) | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 |
EPS (Diluted) | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 |
EBITDA | -31.37M | -62.01M | -128.79M | -100.99M | -71.83M | -27.47M |
EBIT | -39.72M | -70.13M | -135.01M | -104.74M | -73.96M | -28.01M |
Depreciation & Amortization | 8.36M | 8.12M | 6.22M | 3.75M | 2.13M | 537K |
Add to Watchlist
Select watchlists to add or remove GLUE